161 Btk inhibitors: friends or foes?

Introduction Bruton’s tyrosine kinase (BTK) plays a crucial role in the development and maturation of B-cells. A common side effect of Ibrutinib, a BTK inhibitor approved for the treatment of chronic lymphocytic leukaemia (CLL), is active bleeding in the absence of vascular injury. The mechanisms by which ibrutinib alters haemostasis however are currently unclear. The aim of this study was to investigate the effects of ibrutinib on platelet and endothelial cell function in vitro , to determine the mechanisms that underpin ibrutinib-induced bleeding. Methods Platelet rich plasma (PRP) collected from healthy volunteers was treated with increasing concentrations of ibrutinib for 15 min at 37°C, prior to stimulation with collagen (2 µg/ml) or ADP (10 µM). Platelet function and activation were measured by light transmission aggregometry (LTA) and flow cytometry respectively (CD62P + , PAC1 + ) and platelet morphology analysed using scanning electron microscopy (SEM). Platelet signalling pathways were analysed by Western blotting and the generation of endothelial microvesicles (EMVs) from HUVECs enumerated by flow cytometry, following 24 hours treatment with ibrutinib (increasing concentrations from 0.1 µM to 10 µM). Results Ibrutinib significantly reduced collagen-mediated platelet aggregation and activation in a dose-dependent manner (p 2 activation and inhibition of VASP dephosphorylation. Additionally, our results demonstrated that at low concentrations, ibrutinib reduced the generation of pro-thrombotic EMVs, an effect that is reversed at the highest concentrations (p Conclusion Ibrutinib reduces collagen and ADP-mediated platelet aggregation, and activation by reducing phosphorylation of PLCI³2 and PLA 2 and inhibiting VASP dephosphorylation. In addition, ibrutinib also appears to alter endothelial cell function by reducing EMV release. Understanding the mechanisms by which ibrutinib alters haemostasis may lead to the identification of novel antithrombotic targets.